A privately held investment firm operating within a family office structure focuses on early-stage investments across multiple sectors, including life sciences and healthcare. The firm’s sweet spot is pre-seed investments but is open to opportunities from Seed to Series A. The firm’s typical check size is $200k USD per round, with a range of $100k USD to $300k USD, and follow-on investments are possible. While the firm typically does not lead funding rounds, they can serve as technical leads and provide memos for co-investors. The firm is open to opportunities globally.
The firm is primarily interested in therapeutics platforms, enabling technologies and tools for scientists, while also open to considering the more asset-focused companies. The firm is indication agnostic, but tends to avoid investing in companies developing products too similar to those in their current portfolio. In terms of development stages, the firm is open to pre-clinical stage assets with some proof of concepts, which doesn’t necessarily need to be in-vivo. While they are open to engaging with companies in the “idea phase”, it might be too early for investment. The firm prefers to invest early and generally considers assets already in the IND phase or companies generating revenue too late.
The firm does not have specific requirements for the management team. The firm prefers technical teams with complementary skill sets, and are coachable and driven. The firm is an active investor and will consider board or observer seats on a case-by-case basis.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment